Haleon plc reported half-year results for the period ended June 30, 2026, with revenue increasing 2.2% to £5,602m and adjusted operating profit rising 8.2% to £1,364m at constant currency. The company declared an interim dividend of 2.4p per share, a 9% increase year-over-year, and completed £457m in share buybacks against its £500m annual allocation. Haleon maintained its FY 2026 guidance for organic revenue growth of 3-5% and high-single-digit adjusted operating profit growth. The company operates in the consumer health industry, manufacturing and selling over-the-counter medicines and personal care products.
